= .01). However, although the toxicity observed with DCF was anticipated, it was still of concern. Specifically, 82% of patients developed grade 3/4 neutropenia, with 29% experiencing febrile neutropenia. 43 The DCF regimen showed a significant
Search Results
Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
Manish A. Shah and David P. Kelsen
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023
Featured Updates to the NCCN Guidelines
Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Ryan A. Berardi, Dorothy A. Shead, and Deborah A. Freedman-Cass
therapies compared with those receiving only ADT and docetaxel. The populations receiving the triplet and doublet therapies experienced similar rates neutropenia, febrile neutropenia, fatigue, and neuropathy, although grade ≥3 adverse events occurred 63% of
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang
risk of febrile neutropenia, anemia, diarrhea, asthenia, thromboembolic events, or hypertension (associated with bevacizumab). 10 , 11 Studies have suggested that risk of severe toxicity, discontinuation of adjuvant chemotherapy, and even worse overall
Optimizing Stem Cell Mobilization: Lessons Learned
Pamela S. Becker
-filgrastim is indicated to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy drugs associated with a clinically significant incidence of febrile neutropenia. Tbo-filgrastim is approved as a
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis
Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross
), and 25% of all patients treated with chemotherapy would receive granulocyte colony-stimulating factor (G-CSF) pegfilgrastim (on average 2 cycles) for the secondary prevention of febrile neutropenia. 18 For patients who did not receive ODX testing, we
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Featured Updates to the NCCN Guidelines
Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, and Cindy Hochstetler
14.8 months (95% CI, 12.9 months–not estimable), respectively. 17 The most frequent grade ≥3 adverse events were neutropenia (51%), febrile neutropenia (46%), and thrombocytopenia (30%). In a study exploring venetoclax as a salvage agent alone or in
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani, Thomas A. D'Amico, Khaldoun Almhanna, David J. Bentrem, Joseph Chao, Prajnan Das, Crystal S. Denlinger, Paul Fanta, Farhood Farjah, Charles S. Fuchs, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, Catherine Linn, A. Craig Lockhart, Quan P. Ly, Mary F. Mulcahy, Mark B. Orringer, Kyle A. Perry, George A. Poultsides, Walter J. Scott, Vivian E. Strong, Mary Kay Washington, Benny Weksler, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, and Hema Sundar
oxaliplatin (37%) or docetaxel, oxaliplatin, and capecitabine (38%). Febrile neutropenia was reported in only 2% of patients treated with docetaxel, oxaliplatin, and fluorouracil (compared with 14% and 9% for docetaxel/oxaliplatin and docetaxel, oxaliplatin
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba
and control groups were febrile neutropenia (68.0% vs 70.9%), pneumonia (19.6% vs 14.6%), and hypoxia (13.1% vs 15.2%). 40 Other Regimens for Intermediate- or Poor-Risk Cytogenetics Standard-Dose Cytarabine, Anthracycline, and Cladribine A phase III
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
; febrile neutropenia rate was 4% versus 14%, and other toxicities and overall QOL were similar. Docetaxel is included as an upfront option for men with castration-naïve prostate cancer and distant metastases based on results from 2 phase 3 trials (ECOG 3805
Optimizing Systemic Therapy for Bladder Cancer
Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack
). However, in the eligible study population, a 3.2-month improvement in OS was observed with PGC (HR, 0.82; P =.03). Despite this improvement, the incidence of thrombocytopenia, bleeding, and febrile neutropenia were all greater with the 3-drug combination
